Literature DB >> 6407400

Influence of valproic acid on hepatic carbohydrate and lipid metabolism.

C M Becker, R A Harris.   

Abstract

Valproic acid (dipropylacetic acid), an antiepileptic agent known to be hepatotoxic in some patients, caused inhibition of lactate gluconeogenesis, fatty acid oxidation, and fatty acid synthesis by isolated hepatocytes. The latter process was the most sensitive to valproic acid, 50% inhibition occurring at ca. 125 microM with cells from meal-fed female rats. The medium-chain acyl-CoA ester fraction was increased whereas coenzyme A (CoA), acetyl-CoA, and the long chain acyl-CoA fractions were decreased by valproic acid. The increase in the medium chain acyl-CoA fraction was found by high-pressure liquid chromatography to be due to the accumulation of valproyl-CoA plus an apparent CoAester metabolite of valproyl-CoA. Salicylate inhibited valproyl-CoA formation and partially protected against valproic acid inhibition of hepatic metabolic processes. Octanoate had a similar protective effect, suggesting that activation of valproic acid in the mitosol is required for its inhibitory effects. It is proposed that either valproyl-CoA itself or the sequestration of CoA causes inhibition of metabolic processes. Valproyl-CoA formation also appears to explain valproic acid inhibition of gluconeogenesis by isolated kidney tubules. No evidence was found for the accumulation of valproyl-CoA in brain tissue, suggesting that the effects of valproic acid in the central nervous system are independent of the formation of this metabolite.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407400     DOI: 10.1016/0003-9861(83)90602-1

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  30 in total

1.  Inhibition of sterol but not fatty acid synthesis by valproate in developing rat brain in vivo.

Authors:  J P Bolaños; J M Medina; D H Williamson
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

2.  Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.

Authors:  Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

3.  Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro.

Authors:  M F Silva; J P Ruiter; L Illst; C Jakobs; M Duran; I T de Almeida; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

Review 4.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

5.  Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats.

Authors:  Li-fang Zhang; Ling-sheng Liu; Xiao-man Chu; Hao Xie; Li-juan Cao; Cen Guo; Ji-ye A; Bei Cao; Meng-jie Li; Guang-ji Wang; Hai-ping Hao
Journal:  Acta Pharmacol Sin       Date:  2014-01-20       Impact factor: 6.150

6.  Valproate causes metabolic disturbance in normal man.

Authors:  D M Turnbull; D J Dick; L Wilson; H S Sherratt; K G Alberti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

7.  Do criteria exist from urinary organic acids to distinguish beta-oxidation defects?

Authors:  D Rabier; J Bardet; P Parvy; F Poggi; M Brivet; J M Saudubray; P Kamoun
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 8.  Carnitine esters in metabolic disease.

Authors:  H Böhles; A Evangeliou; K Bervoets; I Eckert; A Sewell
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

Review 9.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 10.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.